Dataset Information

A Dynamic Tool to Describe Lamb Growth and Its Use as a Decision Support System.

ABSTRACT: A dynamic model has been developed to simulate aspects of feedlot lamb growth and body composition, including energy and protein requirements, growth rate, composition of gain, and body mass. Model inputs include initial body mass (kg), standard final mass (kg), age (days), and dietary energy concentration (Mcal·kg^-1). The model was assessed as a decision support tool using a dataset of 564 individual measures of final body mass and diet energy. The simulations provide graphical and numerical descriptions of nutrient requirements, composition of gain, and estimates of animal performance over time. The model is accurate and precise, with a root mean squared error of 7.79% of the observed final body mass and a coefficient of determination of 0.89 when simulating the same variable. The model can be used as a reliable decision support tool to estimate final body mass and the days on feed required to reach a certain final mass with precision and accuracy. Moreover, the dynamic model can also serve as a learning tool to illustrate practical principles of animal nutrition, nutrient requirement relationships, and body composition changes. This model holds the potential to enhance livestock management practices and assist producers in making informed decisions about feedlot lamb production.

SUBMITTER: Amaral RM

PROVIDER: S-EPMC11311011 | biostudies-literature | 2024 Aug

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

A Dynamic Tool to Describe Lamb Growth and Its Use as a Decision Support System.

Amaral Rafael Marzall RM Rodrigues Marcelo Teixeira MT Schultz Erica Beatriz EB Reis Cristiano Eduardo Rodrigues CER

Animals : an open access journal from MDPI 20240802 15

A dynamic model has been developed to simulate aspects of feedlot lamb growth and body composition, including energy and protein requirements, growth rate, composition of gain, and body mass. Model inputs include initial body mass (kg), standard final mass (kg), age (days), and dietary energy concentration (Mcal·kg<sup>-1</sup>). The model was assessed as a decision support tool using a dataset of 564 individual measures of final body mass and diet energy. The simulations provide graphical and n ...[more]

PMID: 39123772

Similar Datasets

Project description:BackgroundAppropriate thromboprophylaxis for patients with atrial fibrillation or atrial flutter (AF) remains a national challenge. The recent availability of direct oral anticoagulants (DOACs) with comparable efficacy and improved safety compared with warfarin alters the balance between risk factors for stroke and benefit of anticoagulation. Our objective was to examine the impact of DOACs as an alternative to warfarin on the net benefit of oral anticoagulant therapy (OAT) in a real-world population of AF patients.MethodsThis is a retrospective cohort study of patients with paroxysmal or persistent nonvalvular AF. We updated an Atrial Fibrillation Decision Support Tool (AFDST) to include DOACs as treatment options. The tool generates patient-specific recommendations based upon individual patient risk factor profiles for stroke and major bleeding using quality-adjusted life-years (QALYs) calculated for each treatment strategy by a decision analytic model. The setting included inpatient and ambulatory sites in an academic health center in the midwestern United States. The study involved 5,121 adults with nonvalvular AF seen for any ambulatory visit or inpatient hospitalization over the 1-year period (January through December 2016). Outcome measure was net clinical benefit in QALYs.ResultsWhen DOACs are a therapeutic option, the AFDST recommends OAT for 4,134 (81%) patients and no antithrombotic therapy or aspirin for 489 (9%). A strong recommendation for OAT could not be made in 498 (10%) patients. When warfarin is the only option, OAT is recommended for 3,228 (63%) patients and no antithrombotic therapy or aspirin for 973 (19%). A strong recommendation for OAT could not be made in 920 (18%) patients. In total, 1,508 QALYs could be gained if treatment were changed to that recommended by the AFDST.ConclusionsAvailability of DOACs increases the proportion of patients for whom oral anticoagulation therapy is recommended in a real-world cohort of AF patients and increased projected QALYs by more than 1,500 when all patients are receiving thromboprophylaxis as recommended by the AFDST compared with current treatment.

Project description:BackgroundGiven the opportunities created by artificial intelligence (AI) based decision support systems in healthcare, the vital question is whether clinicians are willing to use this technology as an integral part of clinical workflow.PurposeThis study leverages validated questions to formulate an online survey and consequently explore cognitive human factors influencing clinicians' intention to use an AI-based Blood Utilization Calculator (BUC), an AI system embedded in the electronic health record that delivers data-driven personalized recommendations for the number of packed red blood cells to transfuse for a given patient.MethodA purposeful sampling strategy was used to exclusively include BUC users who are clinicians in a university hospital in Wisconsin. We recruited 119 BUC users who completed the entire survey. We leveraged structural equation modeling to capture the direct and indirect effects of "AI Perception" and "Expectancy" on clinicians' Intention to use the technology when mediated by "Perceived Risk".ResultsThe findings indicate a significant negative relationship concerning the direct impact of AI's perception on BUC Risk (ß = -0.23, p < 0.001). Similarly, Expectancy had a significant negative effect on Risk (ß = -0.49, p < 0.001). We also noted a significant negative impact of Risk on the Intent to use BUC (ß = -0.34, p < 0.001). Regarding the indirect effect of Expectancy on the Intent to Use BUC, the findings show a significant positive impact mediated by Risk (ß = 0.17, p = 0.004). The study noted a significant positive and indirect effect of AI Perception on the Intent to Use BUC when mediated by risk (ß = 0.08, p = 0.027). Overall, this study demonstrated the influences of expectancy, perceived risk, and perception of AI on clinicians' intent to use BUC (an AI system). AI developers need to emphasize the benefits of AI technology, ensure ease of use (effort expectancy), clarify the system's potential (performance expectancy), and minimize the risk perceptions by improving the overall design.ConclusionIdentifying the factors that determine clinicians' intent to use AI-based decision support systems can help improve technology adoption and use in the healthcare domain. Enhanced and safe adoption of AI can uplift the overall care process and help standardize clinical decisions and procedures. An improved AI adoption in healthcare will help clinicians share their everyday clinical workload and make critical decisions.

Project description:PURPOSE:Precision oncology is hindered by the lack of decision support for determining the functional and therapeutic significance of genomic alterations in tumors and relevant clinically available options. To bridge this knowledge gap, we established a Precision Oncology Decision Support (PODS) team that provides annotations at the alteration-level and subsequently determined if clinical decision-making was influenced. METHODS:Genomic alterations were annotated to determine actionability based on a variant's known or potential functional and/or therapeutic significance. The medical records of a subset of patients annotated in 2015 were manually reviewed to assess trial enrollment. A web-based survey was implemented to capture the reasons why genotype-matched therapies were not pursued. RESULTS:PODS processed 1,669 requests for annotation of 4,084 alterations (2,254 unique) across 49 tumor types for 1,197 patients. 2,444 annotations for 669 patients included an actionable variant call: 32.5% actionable, 9.4% potentially, 29.7% unknown, 28.4% non-actionable. 66% of patients had at least one actionable/potentially actionable alteration. 20.6% (110/535) patients annotated enrolled on a genotype-matched trial. Trial enrolment was significantly higher for patients with actionable/potentially actionable alterations (92/333, 27.6%) than those with unknown (16/136, 11.8%) and non-actionable (2/66, 3%) alterations (p=0.00004). Actionable alterations in PTEN, PIK3CA, and ERBB2 most frequently led to enrollment on genotype-matched trials. Clinicians cited a variety of reasons why patients with actionable alterations did not enroll on trials. CONCLUSION:Over half of alterations annotated were of unknown significance or non-actionable. Physicians were more likely to enroll a patient on a genotype-matched trial when an annotation supported actionability. Future studies are needed to demonstrate the impact of decision support on trial enrollment and oncologic outcomes.

Dataset Information

A Dynamic Tool to Describe Lamb Growth and Its Use as a Decision Support System.

Publications

A Dynamic Tool to Describe Lamb Growth and Its Use as a Decision Support System.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets